injectable glp-1 agonists Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies GLP-1 Agonists - Endocrinology Advisor

MK-677 has a much longer half-life, remaining active in the body for about 24 hours

Unlike the DAC version, it mimics the body's natural hormone cycles, which helps reduce the risk of receptor fatigue and long-term complications

Okuyama, T

Having optimal levels of this compound delivers numerous benefits

Figure 1 The safety profile of GLP-1 receptor agonists has been evaluated in several meta-analyses

The endocrine and metabolic adaptation observed in both models may be a strategy to increase life span through a slower cell growing/metabolism, a slower loss of physiologic reserve capacity, a shift of cellular metabolism from cell proliferation to repair activities and a decrease in accumulation of senescent cells